TWD 179.0
(-1.65%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 301.61 Million TWD | -51.15% |
2022 | 617.43 Million TWD | 39.18% |
2021 | 443.63 Million TWD | 246.39% |
2020 | 128.07 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 143.82 Million TWD | -15.58% |
2024 Q1 | 170.37 Million TWD | 60.77% |
2023 Q4 | 105.97 Million TWD | 6.29% |
2023 FY | 301.61 Million TWD | -51.15% |
2023 Q3 | 99.7 Million TWD | 75.27% |
2023 Q2 | 56.88 Million TWD | 45.66% |
2023 Q1 | 39.05 Million TWD | -68.48% |
2022 FY | 617.43 Million TWD | 39.18% |
2022 Q4 | 123.9 Million TWD | 0.0% |
2021 FY | 443.63 Million TWD | 246.39% |
2020 FY | 128.07 Million TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 198.4 Million TWD | -52.016% |
Maxigen Biotech Inc. | 165.82 Million TWD | -81.883% |
SciVision Biotech Inc. | 177.9 Million TWD | -69.541% |
Bionime Corporation | 6.2 Million TWD | -4757.674% |
Pegavision Corporation | 1.65 Billion TWD | 81.786% |